<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164605</url>
  </required_header>
  <id_info>
    <org_study_id>#37977</org_study_id>
    <nct_id>NCT01164605</nct_id>
  </id_info>
  <brief_title>Pilot Study of Raltegravir Lipodystrophy IISP</brief_title>
  <official_title>Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The substitution of raltegravir for the NRTIs will result in some reversal of the long term
      adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with
      the chronic use of NRTIs. Changing the HAART regimen in patients with a sustained virological
      response from a PI plus NRTI to a regimen of the PI plus raltegravir will likely result in
      continued virologic efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, non-controlled, non-randomized, single center study of a treatment regimen of
      a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in combination with
      raltegravir in patients with HIV-1 infection who have been, and continue to be, fully
      controlled on a standard HAART regimen of a PI or an NNRTI plus 2 NRTIs, and the effect of
      the change in regimen on peripheral fat distribution.

      This pilot study will contain 30 patients who will be followed over a period of one year
      starting from the date of the medication change from an NRTI-based regimen to a
      raltegravir-based NRTI-sparing regimen. Potential changes in fat distribution (fat content as
      assessed by fat volume) will be measured with serial MRI's of the thighs.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if the substitution of raltegravir for 2 NRTI's in patients with evidence of peripheral lipoatrophy and who have sustained HIV virological suppression will result in evidence of an increased in volume of peripheral fat within one year.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determining whether the patients will continue to have sustained virological suppression upon switching to a raltegravir-based regimen.</measure>
    <time_frame>eighteen months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining what, if any, adverse effects the patients may develop..</measure>
    <time_frame>eighteen months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>60 tablets (30-day supply)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive

          2. Any patient on a boosted PI plus 2 NRTIs.

          3. Visual evidence peripheral fat wasting

          4. HIV-1 viral load fully suppressed at least 9mths.

        Exclusion Criteria:

          1. Historical resistance to PI patient receiving

          2. No prior exposure to raltegravir, elvitegravir, other HIV-1 integrase inhibitor.

          3. No contraindications to serial MRI scanning.

          4. No contraindications to utilization of raltegravir.

          5. Not currently receiving any medications drug-drug interaction w/ raltegravir.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Berman, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California Institute for Research and Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen M Berman, M.D.,Ph.D.</last_name>
    <phone>(562) 826-8000</phone>
    <phone_ext>2841</phone_ext>
    <email>stephen.berman2@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judy A Gerken, NP</last_name>
    <phone>(562) 826-8000</phone>
    <phone_ext>5452</phone_ext>
    <email>judy.gerken@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bickel M, Eisen J, Stephan C, Crespi CM, Lutz T, Klauke S, Vogl TJ, Jacobi V, Yang OO, Staszewski S, Zangos S. A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophy. HIV Med. 2007 Oct;8(7):413-9.</citation>
    <PMID>17760732</PMID>
  </reference>
  <reference>
    <citation>Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients. D. Ripamonti, F. Maggiolo, E. Bombana, et al. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2010, Cape Town, South Africa.</citation>
  </reference>
  <reference>
    <citation>Raltegravir without a protease inhibitor is highly efficacious in heavily pre-treated individuals. D. Skiest, C. Cohen, D. Barker, M. Gottlieb, et al. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2010, Cape Town, South Africa.</citation>
  </reference>
  <reference>
    <citation>Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.</citation>
    <PMID>20085491</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>May 16, 2012</last_update_submitted>
  <last_update_submitted_qc>May 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NRTI-regimen</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Elvitegravir</keyword>
  <keyword>HIV-1 integrase inhibitor</keyword>
  <keyword>Fat Waste</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

